Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A point mutation in the androgen receptor gene causes complete androgen insensitivity.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Thioredoxin reductase 1 does not affect glucocorticoid receptor activity in hair follicle cells.

Different types of PPARγ are found in varying amounts in human skin and its parts, which could affect how skin treatments work.

Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

A 36-year-old person with a female appearance but male chromosomes was diagnosed with a rare enzyme deficiency affecting sexual development.

Certain genetic variants in ERN1, TACR3, and SPPL2C are linked to when Alzheimer's disease starts.

Newer retinoid drugs are effective for skin conditions but have significant side effects.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

A certain mutation in the fetal alpha 5-reductase gene is linked to a higher risk of late miscarriage.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.

The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.

RORA boosts autophagy in hair follicle stem cells, potentially aiding hair growth.

Mutations in certain receptors can cause diseases and offer new treatment options.

SARMs show promise but need more evidence to prove they're better than traditional androgens.

SARMs may offer benefits by boosting muscle effects without unwanted side effects.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

ALRV5XR is the most effective hair regrowth treatment at 24 weeks.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.

We need better ways to test and understand SARMs to make safer and more effective treatments.